Breaking News
Get 50% Off 0
🧩 Based on my current watchlist, how should I diversify my portfolio?
Ask WarrenAI
Close

Shanghai Fosun Pharmaceutical Group Co Ltd (2196)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
18.72 +0.27    +1.46%
08:59:59 - Closed. Currency in HKD
Type:  Equity
Market:  Hong Kong
ISIN:  CNE100001M79 
  • Volume: 7,325,013
  • Bid/Ask: 18.68 / 18.72
  • Day's Range: 18.12 - 18.81
Shanghai Fosun Pharmaceutical 18.72 +0.27 +1.46%

Shanghai Fosun Pharmaceutical Group Co Ltd Company Profile

 
Get an in-depth profile of Shanghai Fosun Pharmaceutical Group Co Ltd, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryPharmaceuticals
SectorHealthcare
Employees

39309

Equity Type

ORD

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. develops, manufactures, and sells pharmaceutical products in Mainland China and internationally. The company’s product pipeline includes HLX15, a recombinant anti-CD38 human monoclonal antibody injection for treatment of multiple myeloma; HLX13, an anti-CTLA-4 human monoclonal antibody for the treatment of melanoma, renal cell carcinoma, colorectal cancer, hepatocellular carcinoma, non-small cell lung cancer, malignant pleural mesothelioma, and esophageal squamous cell cancer; SZEY-2108 for the treatment of carbapenem resistant enterobacteriaceae (CRE) infection; XH-S003 for the treatment of IgA nephropathy and other glomerular diseases; HLX43, an antibody-drug for the treatment of metastatic solid tumors; XS-03 for the treatment of RAS-mutated advanced solid tumor; OP0595, a nacubactam for the treatment of aerobic gram-negative bacteria; XH-S002 for the treatment of ischemic stroke and transient ischemic attack which are in Phase I; HLX26, anti-LAG-3 humanized monoclonal antibody injection for the treatment of metastatic colorectal cancer; FCN-338 for the treatment of myeloid malignancies; FCN-159 for the treatment of langerhans cell histiocytosis; HLX208, a BRAF V600E inhibitor for the treatment of non-small cell lung cancer which are in phase II; FS-1502, a HER2 humanized monoclonal antibody-monomethyl auristatin F injection for the treatment of HER2-positive locally advanced or metastatic breast cancer; FCN-159 for the treatment of neurofibromatosis; ET-26, a methoxyetomidate hydrochloride for the treatment of general anesthesia which are in phase III. It engages in the import and export of medical equipment; provision of related and other consulting services; medical devices and diagnosis products, and healthcare service; and investment management, as well as involves in the retail and wholesale distribution of medicines. The company was founded in 1994 and is based in Shanghai, China.

Contact Information

Address Building A Fosun Technology Park
No. 1289 Yishan Road Shanghai, 200233
China
Phone 86 21 3398 7000
Fax 86 21 3398 7020

Top Executives

Name Age Since Title
Yuqing Chen 50 2016 Executive Chairman
Xiaohui Guan 54 2013 Executive Co-Chairman
Qiyu Chen 53 2005 Non-Executive Director
Quandi Wang 75 2021 Independent Non-Executive Director
Bing Chen 49 2023 Chairman of the Supervisory Committee
Yucheng Yang 60 2025 Independent Non-Executive Director
Yifang Wu 56 2014 Non-Executive Director
Tze Shan Yu 69 2021 Independent Non-Executive Director
Penghui Chen 53 2025 Independent Non-executive Director
Yimin Guan 75 2007 Supervisor
Kexin Wang 61 2011 Executive Director
Deyong Wen 54 2022 Executive Vice Chairman
Donghui Pan 56 2020 Non Executive Director
Jia Yan 43 2022 Chief Accountant, Co-CFO & Assistant to the President and Employee Director
Wang Lina 39 2024 Employee Supervisor
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

2196 Comments

Write your thoughts about Shanghai Fosun Pharmaceutical Group Co Ltd
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Apple
Continue with Google
or
Sign up with Email